Study Summary
This trial will test the safety of a new combination vaccine for patients with high risk neuroblastoma, as well as its ability to elicit an immune response and shrink tumors.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: 1 year
Trial Safety
Safety Progress
Side Effects for
Trial Design
2 Treatment Groups
Dose Level 1
1 of 2
Dose Level 2
1 of 2
Experimental Treatment
7 Total Participants · 2 Treatment Groups
Primary Treatment: SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 25th, 2021
Last Reviewed: November 7th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.